Post-Approval Economics For New Antibiotics: Post-Marketing Commitments And Ast Development

Post-Approval Economics for New Antibiotics: Post-Marketing Commitments and AST Development

Post-Approval Economics for New Antibiotics: Sales and Marketing

Post-Approval Economics for New Antibiotics: Additional Economic Considerations

Post-Approval Economics for New Antibiotics: Q&A

Bootcamp Post-Approval Economics for New Antibiotics: Introduction & Background (ASM/ESCMID 2019)

Post-Approval Economics for New Antibiotics: Supply Chain Robustness, Inventory Build, and QA

1/5/21 - Examining the Long-term Health & Economic Effects of Antimicrobial Resistance in the U.S.

NASEM Health and Medicine Division

The Economics of Antimicrobial Development

Resistance testing – beyond serial passage experiments

Antibiotic Bootcamps for Developers – Clinical Microbiology for a Development Program

Developing New Antibiotics: What’s the Best Approach to Take?

The Collapse of the Antibiotics Sector – Ryan Cirz

Claremont McKenna College

The financial barrier to developing antibiotics? No big payday for drug companies

A Post-Antibiotic Era Means An End To Modern Medicine As We Know It

The Real Truth About Health

WS 14 – Development of a Sustainable Market for New, Resistance-Breaking Antibiotics

World Health Summit

Resistance to antibiotics could soon kill more people than cancer

World Economic Forum

NEW Antibiotic Summary Cards

Reducing Antibiotic Prescribing in NHS Wales: The Role of Behavioural Economics

Health and Care Research Wales

Drug-resistant infections: the science is on track, but the economics need fixing